New hope for advanced kidney cancer: combo therapy enters phase 3 trial
NCT ID NCT07000149
First seen Oct 31, 2025 · Last updated May 21, 2026 · Updated 24 times
Summary
This study tests two new treatments (volrustomig alone or with casdatifan) against the current standard therapy for people with advanced clear cell kidney cancer that has not been treated before. About 1,116 participants worldwide will take part. The goal is to see if the new combinations help people live longer or keep the cancer from growing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CLEAR CELL RENAL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
La Jolla, California, 92037, United States
-
Research Site
Aurora, Colorado, 80045, United States
-
Research Site
Boston, Massachusetts, 02215, United States
-
Research Site
New York, New York, 10065, United States
-
Research Site
Cleveland, Ohio, 44106, United States
-
Research Site
Nashville, Tennessee, 37232, United States
-
Research Site
Lubbock, Texas, 79430, United States
-
Research Site
East Melbourne, 3002, Australia
-
Research Site
Elizabeth Vale, 5112, Australia
-
Research Site
North Adelaide, 5000, Australia
-
Research Site
Syndey, 4032, Australia
-
Research Site
Beijing, 100142, China
-
Research Site
Guangzhou, 510060, China
-
Research Site
Nanjing, 2100008, China
-
Research Site
Nanning, 530021, China
-
Research Site
Shanghai, 200032, China
-
Research Site
Xiamen, 361003, China
-
Research Site
Batumi, 6010, Georgia
-
Research Site
Tbilisi, 0112, Georgia
-
Research Site
Tbilisi, 0114, Georgia
-
Research Site
Tbilisi, 0186, Georgia
-
Research Site
Busan, 48108, South Korea
-
Research Site
Seongnam-si, 13496, South Korea
-
Research Site
Seongnam-si, 13620, South Korea
-
Research Site
Seoul, 03080, South Korea
-
Research Site
Seoul, 03722, South Korea
-
Research Site
Seoul, 06591, South Korea
-
Research Site
Seoul, 5505, South Korea
-
Research Site
Kaohsiung City, 833401, Taiwan
-
Research Site
Taichung, 404327, Taiwan
-
Research Site
Taichung, 40705, Taiwan
-
Research Site
Tainan, 704, Taiwan
Conditions
Explore the condition pages connected to this study.